ADHD drug gets three more dosage strengths

Article

Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.

Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.

Recent Videos
Alan Percy, MD
Alan Percy, MD
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Image credit: Kyle Dykes
J. Thomas Megerian, MD, PhD, FAAP | Author provided
Colleen Kraft, MD | Image Credit: Children's Hospital Los Angeles
Related Content
© 2024 MJH Life Sciences

All rights reserved.